Multiple significant bortezomib-related toxicities in one patient: case report and literature review.
Bortezomib has shown significant efficacy in the treatment of patients with relapsed multiple myeloma (MM) and is generally well tolerated. We report a 65-year-old male patient undergoing bortezomib therapy for MM who, with the addition of liposomal doxorubicin, presented with severe paralytic ileus, peripheral neuropathy, pruritic rash, and testicular pain. Each of these toxicities was temporally related to the bortezomib-based therapy and the administration of concomitant liposomal doxorubicin. Herein, we discuss the patient's course and briefly review the literature on these bortezomib combination-related toxicities.
Waller
Jeanette M
JM
Department of Medicine, California Pacific Medical Center, San Francisco, CA 94115, USA.
Moretto
John C
JC
Knopf
Kevin B
KB
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D000069286:Bortezomib; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D010146:Pain; D010523:Peripheral Nervous System Diseases / Q000150:complications / Q000175:diagnosis; D011537:Pruritus / Q000150:complications / Q000175:diagnosis; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects*; D013737:Testis / Q000473:pathology
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D004317:Doxorubicin